Drug application
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE (EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE)
Drugs@FDA ANDA 209061 · MYLAN
Key facts
| Drug name | EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE |
|---|---|
| Active ingredients | EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE |
| Application type | ANDA |
| Application number | 209061 |
| Company | MYLAN |
| Dosage forms | TABLET, ORAL |
| Strength | 600MG;200MG;300MG |
| Marketing status | Discontinued |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Sep 5, 2024 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.